COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 23 of 928 for:    Advanced | Neuroendocrine Tumors

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03279601
Recruitment Status : Unknown
Verified September 2017 by Shen Lin, Peking University.
Recruitment status was:  Recruiting
First Posted : September 12, 2017
Last Update Posted : September 12, 2017
Information provided by (Responsible Party):
Shen Lin, Peking University

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : September 1, 2019
Estimated Study Completion Date : September 1, 2020